Close Menu

NEW YORK – The summer of 2017 was a seemingly promising moment for mass spectrometry's move into the clinic, as both Thermo Fisher Scientific and Sciex introduced new, more streamlined machines aimed at the clinical market, and Roche announced its plans to develop a mass spec-based clinical analyzer with Hitachi.

Three years later, the promise has faded somewhat. Sciex has discontinued sales of its system, the Topaz, after seeing limited adoption.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.